Metabolic Profile and Cardiovascular Biomarker Pattern Compared in naive Patients Initiating HAART With TDF-FTC and Raltegravir 400mg BID Vs Darunavir 800 mg Plus Ritonavir 100 mg QD; a One Year Follow-up Observational Study.
Phase of Trial: Phase IV
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Darunavir (Primary) ; Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 24 Jun 2010 Planned number of patients changed from 100 to 120 as reported by ClinicalTrials.gov record.
- 24 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.